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Abstract
Background: Asthma is a major health problem and has significant mortality around the world. Although the
symptoms can be controlled by drug treatment in most patients, effective low-risk, non-drug strategies could
constitute a significant advance in asthma management. An increasing number of patients with asthma are
attracted by acupuncture and moxibustion. Therefore, it is of importance that scientific evidence about the efficacy
of this type of therapy is regarded. Our past researches suggested heat-sensitive moxibustion might be effective in
treatment of asthma. Our objective is to investigate the effectiveness of heat-sensitive moxibustion compared with
conventional drug treatment.
Methods/Design: This study is comprised of a multi-centre (12 centers in China), randomized, controlled trial with
two parallel arms (A: heat-sensitive moxibustion; B: conventional drug). Group A selects heat- sensitive acupoints
from the rectangle region which consist of two outer lateral lines of dorsal Bladder Meridian of Foot-Taiyang, and
two horizontal lines of BL13(Fei Shu) and BL17 (Ge Shu);6 inch outer the first and second rib gap of anterior chest.
Group B treats with fluticasone/salmeterol (seretide). The outcome measures will be assessed over a 3-month
period before each clinic visit at days 15, 30, 60, and 90. Follow-up visit will be at 3, 6 months after the last
treatment session. Adverse event information will be collected at each clinic visit.
Discussion: This trial will utilize high quality trial methodologies in accordance with CONSORT guidelines. It may
provide evidence for the effectiveness of heat-sensitive moxibustion as a treatment for chronic moderate persistent
asthma. Moreover, the result may propose a new type moxibustion to control asthma.
Trial Registration: The trial is registered at Chinese Clinical Trials Registry: ChiCTR-TRC-09000599
Background
Asthma is a common chronic inflammatory disease of
the airways characterized by variable and recurring
symptoms, airflow obstruction, and bronchospasm [1]. It
is also a complex disease involving many cells and med-
iators [2]. Asthma affects 300 million people worldwide
[3], with an increasing prevalence in Western Europe
(5%) and the USA(7%) in particular [4,5]. Despite the
fact that there is still no cure for asthma, it has been
established in a great number of small and large studies
that many patients can reach a good asthma control
with controller treatment [6]. Generally speaking, Medi-
cations used to treat asthma are divided into two gen-
eral classes: quick-relief medications used to treat acute
symptoms and long-term control medications used to
prevent further exacerbation [7]. The therapeutic
options available for patients with asthma depend on
the severity of the condition. Although the symptoms
can be controlled by drug treatment in most patients,
effective low-risk, non-drug strategies could constitute a
significant advance in asthma management [1-3]. There-
fore, an increasing number of patients with asthma are
attracted by complementary and alternative medicine
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asthma patients used some form of unconventional ther-
apy [9].
Acupuncture has traditionally been used in asthma
treatment in China and is increasingly applied for this
purpose in Western countries. Moxibustion is a tradi-
tional Chinese method of acupuncture treatment, which
utilizes the heat generated by burning Moxa (it is also
called Mugwort or Moxa) to stimulate the acupuncture
points. The technique consists of lighting a moxa-stick
and bringing it close to the skin until it produces hyper-
emia due to local vasodilatation. The intensity of moxi-
bustion is just below the individual tolerability
threshold. Moxibustion has anti-inflammatory or immu-
nomodulatory effects against chronic inflammatory con-
ditions in humans [10]. Moxibustion method for
treatment of asthma diverse curative effect and its
mechanism may be due to improve lung function,
antagonize of inflammatory mediators, modulate of
immune function, regulate the role of cyclic nucleotide
levels, and can also affect the neuroendocrine network
and inflammatory cells [11-14]. Therefore, these inflam-
matory substances may be reduced and weakened by
moxibustion. Especially for chronic persistent asthma,
moxibustion may get a better effect.
Although firm evidence has not been established, the
results of some clinical trials suggest that acupuncture
and moxibustion may effective in the treatment of
asthma [15-18]. However, these researches do not con-
firm the efficacy of acupuncture and moxibustion. This
may be because all relevant RCTs were limited by meth-
odological defects, including inappropriate sample size,
variability of acupuncture and sham protocols, and miss-
ing information. Therefore, rigorous high-quality rando-
mized controlled trials are needed.
Thinking about moxibustion itself, the selection of loca-
tion for manipulating Moxa plays an important role in
obtaining good effects [19]. The moxibustion point loca-
tion may be connected with the changes in the condition
of the disease. Our team of experts were astonished to
find that the main factor in selecting the location of acu-
puncture points is link with the area which is affected by
disease, not only the standardized fixed position.
In the human nature, there are two state of being in
acupuncture points, the sensitized or awake state and
the rest state. When the human body suffers form dis-
ease, the acupoints on the surface of the body are stimu-
lated and sensitive by various stimulants including heat.
The specific areas stimulated by heat are then called
“heat-sensitive points”. One of the characteristics of
these areas is that they are specific or closely related to
acupuncture points and have the same clinical effect
as “a small stimulation induces a large response”.
The Inner Canon of Huangdi or Yellow Emperor’sI n n e r
Canon is an ancient Chinese medical text that has been
treated as the fundamental doctrinal source for Chinese
medicine for more than two millennia and until today.
According with its core viewpoint and theory, acupoint
is described and understood with the state, which is cer-
tain area of the body surface in the course of diseases.
Among the changes, sensitized status is the common
one, described that acupoints on the body surface may
be sensitized in the course of diseases. Acupoint heat-
sensitization is a type of acupoint sensitization. Our
research found that the heat-sensitive phenomenon to a
point or an area is a new type of reaction featured in a
pathological state [20-23]. We applicated the acupoint
heat-sensitization phenomenon and rule in the past
twenty years. Our team experimental evidence indicates
that the state of a point might change from the rest
state to the heat sensitized state while suffering from
diseases. Its characteristic was thought that these special
acupoints might produce heat response and farther
warm sensation, as a result of stimulation of moxibus-
tion heat. If we can search out these heat-sensitized acu-
points associating with pathological state, good effect
will be achieved. Therefore, selecting the heat-sensitized
acupoint may obtain therapeutic effect far better than
acupuncture and moxibustion at acupoints of routine
rest state. So we defined the approach which treated
various diseases through heat-sensitized acupoint, as
heat- sensitive moxibustion therapy. We carried out
many clinical trials to test and verify the efficacy of
heat-sensitized acupoint, such as myofascial pain syn-
drome [22], lumbar disc herniation [24], pressure sores
[25] and knee osteoarthritis [26]. The result of clinical
trials almost suggested superiority effect of heat-sensi-
tized acupoint and encouraged us to proceed. Hence, we
planned a rigorous multi-centre randomized controlled
trial with a large sample size.
Method/design
Objective
T h ea i mo ft h i ss t u d yi st oi n v estigate the effectiveness
of heat-sensitive moxibustion compared with flutica-
sone/salmeterol (seretide) in patients with chronic mod-
erate persistent asthma in China.
Outcome measures
Primary outcome
At present, the goal of asthma care is to achieve and
maintain control of clinical manifestation of the disease
[27,28]. Hence, we use Asthma Control Test (ACT) to
quickly access asthma control, a simple 5-question tool
that is completed by the patient and parents/caregivers
and recognized by the National Institutes of Health
(Table 1) [29,30]. Patients should write the number of
each answer in the score box provided, and then add up
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before treatment and at days 15, 30, 60, and 90 in the
treatment period. Follow-up visit will be at 3, 6 months
after the last treatment session.
Secondary outcomes
Measurement of lung function provides an assessment
of the severity, reversibility, and variability of airflow
limitation. Forced expiratory volume in 1 s (FEV1) and
peak expiratory flow (PEV) will be used in this trial.
Attack frequency also will be assessed. These outcomes
also will be assessed before treatment and at days 90 in
the treatment period. Follow-up visit will be at 3, 6
months after the last treatment session. Adverse event
information will be collected at each clinic visit.
Design
A multi-centre, randomized, two parallel arms (group A
and B) and assessor blinded, positive controlled trial will
be conducted at the twelve centers in China (Table 2).
The study will be sequentially conducted as follows: a
run-in period of one week prior to randomization, a
treatment period of 90 days, and a follow-up period of
six months. At the end of the run-in period, participants
will be randomized to the heat-sensitive moxibustion
group or the drug group by the central randomization
system (Figure 1). This system is provided by China
Academy of Chinese Medical Sciences, which adopted
the computer telephone integration (CTI) technology to
integrate computer, internet and telecom. The random
number list will be assigned by interactive voice
response (IVR) and interactive web response (IWR) [31].
The success of blinding will be assessed at each partici-
pant’s last visit. Assessor who did not participate in the
treatment and who is blinded to the allocation results
will perform the outcome assessment.
Eligibility
Inclusion criteria
According to the guideline of asthma treatment and
prevention in China (GATPC) [32], patients are divided
into three types, including acute exacerbation, chronic
persistent and clinical remission. Severity grade of
asthma in GATPC is described in Table 3. Our trial will
only choose participants with chronic moderate persis-
tent asthma (Figure 1).
Patients will be required to complete the baseline
asthma diary. Written informed consent will be obtained
from each participant. Participants 18~65 years of age will
be recruited from outpatient and inpatient in 12 centers.
Standard of diagnosis listed as follows: (1) Common signs
and symptoms of asthma include: recurrent wheezing,
coughing, trouble breathing, chest tightness; (2) Symptoms
that occur or worsen at night, and symptoms that are trig-
g e r e db yc o l da i r ,e x e r c i s eo re x p o s u r et oa l l e r g e n s ;( 3 )
Scattered or diffuse expiratory wheezing sound could be
heard in the lungs in attack; (4) The above symptoms will
be relieved or disappear after treatment; (5) Ruling out
conditions other than asthma; (6) When typical clinical
symptoms can not be observed, lung function tests should
be used to confirm, such as positive challenge test, positive
bronchodilator test(an increase in FEV1 of ≥12% and ≥200
ml), and mutation rate of PEF≥20% one day/two weeks.
Since the research involves moderate asthma (grade III),
the inclusion criteria will restrict the following conditions:
According to the below GATPC diagnosis standard,
meanwhile, heat-sensitivity appears within the rectangle
area which consist of two outer lateral lines of dorsal Blad-
der Meridian of Foot-Taiyang, and two horizontal lines of
BL13 (Fei Shu) and BL17 (Ge Shu); 6 inch outer the first
and second rib gap of anterior chest. Participants will be
instructed to stop asthma symptomatic relief medication
Table 1 Asthma Control Test (ACT) for people 12 yrs and older.
1. In the past 4 weeks, how much of the time did your asthma keep you from getting as much done at work, school or at home? Score
All of the time
①
Most of the time
②
Some of the time
③
A little of the time
④
None of the time
⑤
2. During the past 4 weeks, how often have you had shortness of breath?
More than once a day
①
Once a day
②
3 to 6 times a week
③
Once or twice a week
④
Not at all
⑤
3. During the past 4 weeks, how often did your asthma symptoms (wheezing, coughing, shortness of breath, chest tightness or pain)
wake you up at night or earlier than usual in the morning?
4 or more nights a week
①
2 or 3 nights a week
②
Once a week
③
Once or twice
④
Not at all
⑤
4. During the past 4 weeks, how often have you used your rescue inhaler or nebulizer medication (such as albuterol)?
3 or more times per day
①
1 or 2 times per day
②
2 or 3 times per week
③
Once a week or less
④
Not at all
⑤
5. How would you rate your asthma control during the past 4 weeks?
Not controlled at all
①
Poorly controlled
②
Somewhat controlled
③
Well controlled
④
Completely controlled
⑤
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provided the usual care instruction for asthma.
Exclusion criteria
Participants will be excluded if they have other diseases
that also cause breathlessness or dyspnea, such as
bronchiectasis, cor-pulmonale, pulmonary fibrosis,
tuberculosis, pulmonary abscess, chronic obstructive
pulmonary disease and so on. Participants will not be
eligible if the female are in the duration of pregnancy or
lactation. The following conditions are also excluded
items: Complicated with serious life-threatening
diseases, such as heart and brain blood vessels, liver,
kidney and hematopoietic system disease and psychotic
patients; Hormone-dependent type patients, or the peo-
ple who used adrenal cortical hormone (intravenous,
intramuscular injection, subcutaneous injection and oral
administration) within 4 weeks before recruiting.
Treatment protocol
Heat-sensitive moxibustion
Moxibustion will be performed by certified acupuncture
medical doctors at 12 centers. Qualified specialists of
acupuncture in traditional Chinese medicine with at
least five years of clinical experience will perform the
acupuncture in this study. All treatment regimens will
be standardized between 12 centers practitioners via
video, hands-on training and internet workshops. Parti-
cipants will be randomly assigned to the heat-sensitive
moxibustion group, or the drug group. In the former
g r o u p ,a2 2m m( d i a m e t e r )×1 6 0m m( l e n g t h )m o x a -
sticks (Jiangxi Hospital of Traditional Chinese Medicine,
China) will be used. The patient is usually in the com-
fortable position for treatment, with 24°C~30°C tem-
perature in the room. He should wear loose clothes.
For the heat-sensitive moxibustion group, the moxa-
sticks are lit by the therapist and held over the rectangle
area which consist of two outer lateral lines of dorsal
Bladder Meridian of Foot-Taiyang, and two horizontal
lines of BL13(Fei Shu) and BL17 (Ge Shu);6 inch outer
the first and second rib gap of anterior chest. The
warming suspended moxibustion about distance of 3 cm
above the skin are used to search the acupoint heat-sen-
sitization phenomenon. The following patients sensation
will suggest the special heat-sensitization acupoint: dia-
thermanous sensation due to moxa-heat, defining as the
heat sensation conducting from the Moxa local skin sur-
face into deep tissue, or even into the thoracic cavity;
expand heat sensation due to moxa-heat, defining as the
Table 2 List of 12 clinical centers
Name City Province
Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine(TCM) Nanchang Jiangxi
Guangdong Hospital of Traditional Chinese and Western Medicine Foshan Guangdong
Wuhan the First Hospital Wuhan Hubei
Guangdong Hospital of TCM Guangzhou Guangdong
Guangzhou University of TCM Guangzhou Guangdong
Guangdong Disabled Soldier Hospital Guangzhou Guangdong
Affiliated Hospital of Shandong University of TCM Jinan Shandong
Suzhou Hospital of TCM Suzhou Jiangsu
The First Affiliated Hospital of Zhejiang University of TCM Hangzhou Zhejiang
The First Affiliated Hospital of Chongqing Medical University Chongqing Chongqing
The First Affiliated Hospital of Nanchang University Nanchang Jiangxi
Nanchang Hospital of Traditional Chinese and Western Medicine Nanchang Jiangxi
Figure 1 The flow diagram is intended to depict the passage
of participants through this RCT.
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around the moxa point; transfer heat sensation due to
moxa-heat, defining as the heat sensation transferring
along some pathway, or even to the arms. The therapists
mark the point as heat-sensitive acupoint. We try our
best to seek all the special acupoints in each patient by
the repeated manipulation.
The therapists begin to treat patients from the most
heat-sensitive intensity acupoint. Treatment sessions
end when patients are feel the acupoint heat-sensitiza-
tion phenomenon disappeared. Generally speaking, we
find the time range from 30~60 minutes. In 1
st month,
patients receive the treatment once a day in the first
eight days, and 12 times treatment in the next twenty-
two days. Treatments will be given 15 times a month
for the remaining two months.
Drug group
In recent years, considerable insight has been gained in
to the optimal management of adult asthma. Those with
persistent asthma are usually not well controlled without
inhaled corticosteroids (ICS). Adding a long-acting beta-
agonist (LABA) to ICS appears to be well controlled
[33]. The combination of an ICS and LABA is preferred
in these patients, and is better than doubling or even
quadrupling the dose of ICS to achieve better asthma
control and reduce exacerbation risks [34,35]. Two such
combinations, salmeterol xinafoate and fluticasone pro-
pionate (SFC, Seretide(tm)) and formoterol and budeso-
nide (FBC, Symbicort(tm)) are widely used and have
been shown to be effective in controlling asthma of
varying severity in adults and children [36-38].
Therefore, we selected the Seretide Accuhaler, con-
taining two medicines, fluticasone propionate and sal-
meterol xinafoate, which is the mainstay of current
asthma treatment. This drug is recommended by
GINA as a regular treatment. Our trial uses salme-
terol/ﬂuticasone 50 μg/250 μg twice a day. Patients
receive the treatment for a total of 180 sessions over
90 days.
Statistical methods
Statistical analysis plan
We will conduct analysis on an intention-to-treat basis,
including all randomized participants with at least one
measurable outcome report. Analyses will be conducted
using 2-sided significance tests at the 5% significance
level. An analysis using the Cochran-Mantel-Haenszel
procedure will be done to asses center effect. The statis-
tician conducting the analyses will remain blind to treat-
ment group and data will only be unblinded once all
data summaries and analyses are completed. All analyses
will be conducted in the SAS statistical package pro-
gram (ver. 9.1.3).
Baseline data
Baseline characteristics will be shown as mean ± stan-
dard deviation (SD) for continuous data including age,
previous duration, and so on. As for participants’ gen-
der, n (%) of male and female in each group will be
shown as baseline characteristics. We will conduct
between-group comparison in baseline using two-sample
t-test or Wilcoxon rank sum test for continuous data
and using Chi-square test or Fisher’s exact test for gen-
der composition considering p < 0.05 as statistically
significant.
If any imbalances in baseline characteristics between
groups are encountered, we will conduct ANCOVA
(analysis of covariance) using these imbalanced variables
as covariates and allocated group as fixed factor.
Outcome data
For primary and secondary outcome measures, these
will be summarized descriptively (mean, SD, median,
minimum and maximum) at each time point by treat-
ment group. The t-test, Mann-Whitney U and Wilcoxon
test were used for comparison of variables, as
appropriate.
All adverse events reported during the study will be
included in the case report forms; the incidence of
adverse events will be calculated. The percentage of sub-
jects with adverse events in each group will be
Table 3 Clinical classification of severity in GATPC
Characteristic Intermittent (Grade I) Mild (Grade II) Moderate (Grade III) Severe (Grade IV)
symptoms Less than once week More than once week, < once
a day
Everyday Everyday
Limitation of
activities and
sleep
Transient May be affect activities and
sleep
Affect activities and sleep Frequent
Nocturnal of
symptoms/
awakening
Less than twice a month More than twice a month,
< once a week
More than once week Frequent
Lung function
(PEF or FEV1)
≥80% predicted (FEV1)or
personal best (PEF); mutation
rate < 20%
≥80% predicted (FEV1)or
personal best (PEF); mutation
rate 20%~30%
60%~79% predicted (FEV1)or
personal best (PEF); mutation
rate > 30%
< 60% predicted (FEV1)or
personal best (PEF); mutation
rate > 30%
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Fisher’s exact test.
Dropped or missing data Reasons for dropped or miss-
ing data will be explored by descriptively. Missing data
will be replaced according to the principle of the last
observation carried forward.
Follow-up data T h ep r i m a r yo u t c o m ew i l lb et h eA C T
scores. The primary analysis will compare the two
groups in 3 months. A secondary analysis will compare
the two groups at 6,9 months to assess if any differences
between groups have been maintained over time.
Loss to follow-up is likely to lead to biased estimates
of intervention effect. We will try to avoid bias due to
attrition by carefully following up the participants in
both groups. We will phone participants who fail to
complete questionnaires after a second reminder. We
anticipate a 20% loss to follow-up in this trial, and will
implement procedures to minimize loss to follow-up
and patient withdrawal, and where possible, we will col-
lect information on reasons for patient withdrawal.
Data integrity
The integrity of trial data will be monitored by regularly
scrutinizing data sheets for omissions and errors. Data
will be double entered and the source of any inconsis-
tencies will be explored and resolved.
Sample size
We wished to estimate the sample size according to non-
inferiority clinical trial between the heat-sensitive and drug
group. Sample size depends on the level of confidence cho-
sen, the risk of type II error (or desired power), and δ.T h e
parameter margin of non-inferiority δ can be specified as a
difference in means or proportions. It is often chosen as
the smallest value that would be a clinically important
effect. To determine δ, we carried out a small sample pilot
study previously. The primary endpoint chosen was ACT.
The result of outcome showed difference in means
between the two groups approximately was 0.45. The
choice of δ = 0.15 (30% of Δ) appeared to be reasonable
based on clinical relevance and statistical judgment.
If we apply a two-sided 5% significance level(δ =0 . 1 5 ,
a =0 . 0 5 ,b = 0.2), 95% power the calculated required
sample size is approximately 120 participants in each
group, according to the following equation. Allowing for
a 20% loss to follow up, a total of 144 participants will
be required in each group, with 288 participants in total.
n
UU
PP =×
+ ()
×− 21
2
2


()
Adverse events
We define adverse events as unfavorable or unintended
signs, symptoms or disease occurring after treatment
that are not necessarily related to the moxibustion
intervention. In every visit, adverse events will be reported
by participants and examined by the practitioner.
Ethics
Written consent will be obtained from each participant.
This study was approved by all relevant local ethics
review boards. Ethics Committee of Affiliated hospital of
Jiangxi Institute of Traditional Chinese Medicine had
approved this trial: code issued by ethic committee is
2008(13).
Discussion
To our knowledge, the goal of asthma care is to achieve
and maintain control of clinical manifestations of the
disease for prolong periods. When asthma is controlled,
patients can prevent most attacks, avoid troublesome
symptoms day and night, and keep physically active [1].
Acupuncture therapy was often perceived as an effective
option to control asthma successfully by patients with
chronic asthma. The use of acupuncture in asthma
patients is increasing as an adjunct and also as a substi-
tute for effective and proven therapies [39]. In China,
moxibustion are considered as an ancient treatment to
prevent and control asthma, and still widely used today.
A number of clinical trial suggested moxibustion as one
of traditional acupuncture therapy, should effective in
the treatment of asthma. But the methodological pro-
blems of published trials haunt us the trust of moxibus-
tion. Therefore, we design this rigorous clinical trials
meeting the CONSORT statement and guidelines to
guarantee a high internal validity for the results.
At present, various conventional medications are used
to slow down and control with the disease. An ICS/
LABA combination in a single inhaler represents a safe,
effective and convenient treatment option, and recom-
mended by GINA. So, we selected the fluticasone/salme-
terol (seretide) as the control treatment in the protocol.
Actually, the aim of this trial is to search an effective
CAM treatment to control asthma, as good as conven-
tional drug. The focused features of moxibustion are
low cost, less adverse event and low risk.
According to the current theory of traditional Chinese
medicine, moxibustion resulting from the burning of
Moxa produces the radiant heat and drug effects to acu-
points. This treatment penetrates deeply into the body,
restoring the balance and flow of vital energy or life
force through acupoints. So the selected of location for
manipulating Moxa plays an important role in obtaining
good effects. Generally speaking, the location acupoints
are fixed along meridians. The conventional moxibus-
tion is considered as improving general health and treat-
ing diseases by stimulating these fixed acupoints. And
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tion as the indicator of moxibustion’se f f e c t .H o w e v e r ,
our clinical experience and observation in the past sug-
gested that stimulating these fixed acupoints might not
the best treatment site for moxibustion. In the human
nature, there are two states of acupoints, the stimulated
or awake state and the rest state. When the human
body suffers form disease, the acupuncture points on
the surface of the body are stimulated and sensitive by
various stimulants including heat. And acupoint heat-
sensitization is a type of acupoint sensitization. Acu-
point is more than fixed skin site but external sensitive
point reflecting the diseases. Therefore, acupoint is vari-
able and depends on the pathological state. Traditional
fixed acupints are thought as indicators to searching
specific sensitive acupoint. That is, traditional fixed acu-
pints don not consider the state as the key factor to
local the acupoint, so the course of fixing the position is
imprecisely.
When we light the Moxa hold over the heat-sensitive
acupoints, the patients will produce some heat-sensitiza-
tion phenomenon. The following patients sensation will
suggest the special heat-sensitization acupoint: diather-
manous sensation due to moxa-heat, defining as the
heat sensation conducting from the moxa local skin sur-
face into deep tissue, or even into the thoracic cavity;
expand heat sensation due to moxa-heat, defining as the
heat sensation spreading the surrounding little by little
around the moxa point; transfer heat sensation due to
moxa-heat, defining as the heat sensation transferring
along some pathway, or even to the arms.
Acupuncture and moxibustion originated in China
several thousands of years ago. The ancient Chinese
medical classic Huáng Dì Nèi Jīng translated as ’The Yel-
low Emperor’s Inner Classic’ has been treated as the fun-
damental doctrinal source for Chinese medicine for
more than two thousand years. According to the chapter
Annotations on ‘The Yellow Emperor’sI n n e rC l a s s i c-
chapter: jiu zhen shi er yuan’(translated as ‘Nine Needles
and twelve yuan-primary acupoints”),i ts a y s :“the so-
called joints are the places where Shenqi flows in and
out, not just referring to skin, muscles, sinews and
bones.” This explains that the acupuncture points are
not located according to the flesh and bones, which by
definition have a fixed location, but they are alive and
h a v ead y n a m i cs t a t ed u et ot h ea c t i v i t yo f“shen-qi”.I n
the Huáng Dì Nèi Jīng Ling Shu (黄帝内经灵枢)t r a n s -
lated as “Annotations on ‘The Yellow Emperor’sI n n e r
Classic’ - chapter: jiu zhen shi er yuan(translated as
‘Nine Needles and twelve yuan-primary acupoints”),i t
says: “so the disease of the Five Zang-organs can be
treated by needling the twelve Yuan-Primary acu-
points. The twelve Yuan-Primary acupoints show how
the five Zang-Organs receive the nutrients of food
and water and how Essence-Qi is infused into the
three hundred and sixty-five joints. That is why the
disease of the Five Zang-Organs are manifested over
the twelve Yuan-Primary acupoints which show cer-
tain manifestations. Awareness of the twelve Yuan-
Primary and observation of the manifestation to know
the pathological changes of the Five Zang-Organs”.
W ec a nl e a r na ni m p o r t a n tf a c tf r o mt h i ss e c t i o no f
the classical text. It clearly states that acupuncture
points reflect the pathological state of the internal dis-
eases and can be stimulated in treatment. Physically,
people are not always aware of the existence of the
acupuncture points. In contrast, patients can usually
feel some changes in the area of the acupuncture
point when affected by disease. Through the obser-
vation of these changes, the ancient doctors located
the acupuncture points. In the Annotations on ‘The
Yellow Emperor’s Inner Classic - chapter: ‘back-shu acu-
points’,i ts t a t e s :“The Feishu (BL13) acupoint is
located between the third thoracic vertebra. The Xin-
shu (BL15) acupoint is located below and lateral to
the fifth thoracic vertebra. The Geshu (BL17) acupoint
is located below and lateral to the seventh thoracic
vertebra. The Ganshu (BL18) acupoint is located
below and lateral to the ninth thoracic vertebra. The
Pishu (BL20) acupoint is located below and lateral to
the eleventh thoracic vertebra. The Shenshu (BL23)
is located below and lateral to the fourteenth thoracic
vertebra. These acupoints are all located beside the
spinal column and 3 cun away from the spinal col-
umn. The method to locate these acupoints is to
press the regions. When pressed, the patient will feel
aching and distending or feel that the original pain is
relieved.” This section of the classical text illustrated
that the back shu points are found by founding the
sensitive areas on the skin. In the Annotations on ‘The
Yellow Emperor’s Inner Classic - chapter: ‘five xie’ (trans-
lated as ‘five kinds of pathogenic factor’)it says:
“cough involving the shoulder and back, to treat such a
disease, acupoints located on the lateral side of the chest
and lateral to the third thoracic vertebra can be needled.
Before applying acupuncture, the doctor may use his fin-
gers to quickly press the concerned region; the place
where the patient feels comfortable when pressed is the
acupoint and should be needled”. From this section, we
can conclude that the sensitivity of the points is the
key factor to locate the position of the acupuncture
points.
Among the changes, sensitized status is the common
one, described that acupoints on the body surface may
be sensitized with various types of sensitization. This
sensitized acupoint is not only the pathological phenom-
enon reflecting the diseases but also stimulating location
with acupuncture and moxibustion. Acupoint heat-
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Page 7 of 9sensitization is a type of acupoint sensitization, which
derived from our clinical experience and research in
past twenty years. The special acupoint makes accor-
dance with the classical thought and theory from the
Inner Canon of Huangdi.
Our empirical evidence engaged us to formulate the
following hypothesis: selecting the heat-sensitized acu-
point may obtain therapeutic effect in asthma. The main
aim of this trial is to test and verify the hypothesis. If
we can confirm this hypothesis, the results of our trial
will be helpful to supply the evidence on searching bet-
ter safe approach to control asthma.
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